Cormorant Asset Management’s Jade Biosciences JBIO Stock Holding History

Cormorant Asset Management’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-30,566	Closed	-$31.6M	–	54
2024 Q1	$31.6M	Sell	30,566 -4,054	-12%	-$3.1M	1.39%	22
2023 Q4	$27.4M	Sell	34,620 -10,000	-22%	-$5.1M	1.31%	22
2023 Q3	$21.2M	Hold	44,620	–	–	1.24%	22
2023 Q2	$26.8M	Hold	44,620	–	–	1.53%	19
2023 Q1	$31.5M	Sell	44,620 -11,298	-20%	-$9.37M	2.07%	14
2022 Q4	$57.3M	Sell	55,918 -10,673	-16%	-$7.75M	3.85%	6
2022 Q3	$38.6M	Buy	66,591 +17,143	+35%	+$11.4M	2.72%	10
2022 Q2	$27.1M	Sell	49,448 -2,857	-5%	-$1.36M	2.1%	17
2022 Q1	$33.6M	Hold	52,305	–	–	2.58%	13
2021 Q4	$21.6M	Sell	52,305 -5,715	-10%	-$2.89M	1.28%	24
2021 Q3	$42M	Hold	58,020	–	–	1.71%	17
2021 Q2	$44.6M	Buy	+58,020	New	+$46.4M	1.74%	20

Other funds holding JBIO

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2B AUM 117.41% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return